AN INTERNATIONAL, MULTICENTER, RANDOMIZED, OPEN-LABEL, PARALLEL EFFICACY AND

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 评估与帕米磷酸钠治疗的患者相比，唑来膦酸治疗的严重骨发育不全患者在12个月时腰椎骨密度相对于基线的百分比变化。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. To assess the percentage change in lumbar spine bone mineral density at month 12 relative to baseline in zoledronic acid treated patients with severe oseogenisis imperfecta compared to pamidronate treated patients.